Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen. In Gilead's ...
After receiving a series of immunotherapies, most people with HIV in a small study kept their virus levels low for several months—and one person for more than a year and a half—without their usual ...
Since the human immunodeficiency virus (HIV) was identified in 1983, roughly 91.4 million people around the world have contracted the virus and an additional 44.1 million have died from related causes ...
Since the human immunodeficiency virus (HIV) was identified in 1983, roughly 91.4 million people around the world have contracted the virus and an additional 44.1 million have died from related causes ...
Health officials in Bungoma County have raised concern over a growing trend in which men avoid HIV testing and instead depend on their wives’ test results to determine their own status. County ...
UCSF researchers say they have found a treatment for HIV that shows potential as a long-term solution for the chronic disease that up until this point has been held at bay in patients through the use ...
JOHANNESBURG, Nov 20 (Reuters) - China has pledged $3.49 million to support HIV prevention services in South Africa over the next two years under a new partnership facilitated by UNAIDS, Beijing's ...
Merck & Co. said a late-stage study of its proposed oral doravirine/islatravir regimen met its key goals in adults with HIV-1 infection who haven't previously taken antiretroviral treatments. Merck on ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease. Integrase strand ...
Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically ...
Instagram is rolling out a new test that lets select users fine-tune what they’d like to see in their Reels and Explore feeds. Here’s what it looks like. Instagram lead Adam Mosseri took to Threads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback